174 related articles for article (PubMed ID: 23154571)
1. Unexpected doxorubicin-mediated cardiotoxicity in sisters: possible role of polymorphisms in histamine n-methyl transferase.
Sachidanandam K; Gayle AA; Robins HI; Kolesar JM
J Oncol Pharm Pract; 2013 Sep; 19(3):269-72. PubMed ID: 23154571
[TBL] [Abstract][Full Text] [Related]
2. Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms.
Scott JM; Khakoo A; Mackey JR; Haykowsky MJ; Douglas PS; Jones LW
Circulation; 2011 Aug; 124(5):642-50. PubMed ID: 21810673
[No Abstract] [Full Text] [Related]
3. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.
Krajinovic M; Elbared J; Drouin S; Bertout L; Rezgui A; Ansari M; Raboisson MJ; Lipshultz SE; Silverman LB; Sallan SE; Neuberg DS; Kutok JL; Laverdière C; Sinnett D; Andelfinger G
Pharmacogenomics J; 2016 Nov; 16(6):530-535. PubMed ID: 26345518
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study.
Lotrionte M; Palazzoni G; Abbate A; De Marco E; Mezzaroma E; Di Persio S; Frati G; Loperfido F; Biondi-Zoccai G
Int J Cardiol; 2013 Aug; 167(3):1055-7. PubMed ID: 23174173
[No Abstract] [Full Text] [Related]
5. Genotyping the risk of anthracycline-induced cardiotoxicity.
Deng S; Wojnowski L
Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin cardiotoxicity in the elderly: old drugs and new opportunities.
Carver JR; Schuster SJ; Glick JH
J Clin Oncol; 2008 Jul; 26(19):3122-4. PubMed ID: 18591552
[No Abstract] [Full Text] [Related]
7. Single-nucleotide polymorphisms in aldo-keto and carbonyl reductase genes are not associated with acute cardiotoxicity after daunorubicin chemotherapy.
Lubieniecka JM; Liu J; Heffner D; Graham J; Reid R; Hogge D; Grigliatti TA; Riggs WK
Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):2118-20. PubMed ID: 23001242
[TBL] [Abstract][Full Text] [Related]
8. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2006 Oct; (4):CD005006. PubMed ID: 17054231
[TBL] [Abstract][Full Text] [Related]
9. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2010 May; 2010(5):CD005006. PubMed ID: 20464735
[TBL] [Abstract][Full Text] [Related]
10. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2010 Mar; (3):CD005006. PubMed ID: 20238335
[TBL] [Abstract][Full Text] [Related]
11. Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the "European Paediatric Oncology Off-patents Medicines Consortium" (EPOC) Trial.
Hellmann F; Völler S; Krischke M; Jamieson D; André N; Bisogno G; Boddy A; Hempel G
Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):413-422. PubMed ID: 31981210
[TBL] [Abstract][Full Text] [Related]
12. Rehabilitative exercise in a rat model of doxorubicin cardiotoxicity.
Hydock DS; Lien CY; Jensen BT; Parry TL; Schneider CM; Hayward R
Exp Biol Med (Maywood); 2012 Dec; 237(12):1483-92. PubMed ID: 23354407
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity of doxorubicin and other anthracycline derivatives.
Jain D
J Nucl Cardiol; 2000; 7(1):53-62. PubMed ID: 10698235
[No Abstract] [Full Text] [Related]
14. Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice.
Huang C; Zhang X; Ramil JM; Rikka S; Kim L; Lee Y; Gude NA; Thistlethwaite PA; Sussman MA; Gottlieb RA; Gustafsson AB
Circulation; 2010 Feb; 121(5):675-83. PubMed ID: 20100968
[TBL] [Abstract][Full Text] [Related]
15. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin-induced cardiotoxicity is suppressed by estrous-staged treatment and exogenous 17β-estradiol in female tumor-bearing spontaneously hypertensive rats.
Pokrzywinski KL; Biel TG; Rosen ET; Bonanno JL; Aryal B; Mascia F; Moshkelani D; Mog S; Rao VA
Biol Sex Differ; 2018 Jun; 9(1):25. PubMed ID: 29907135
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin modulates imbalance of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in doxorubicin-induced cardiotoxicity.
Chen X; Guo Z; Wang P; Xu M
Heart Lung Circ; 2014 Aug; 23(8):772-7. PubMed ID: 24685074
[TBL] [Abstract][Full Text] [Related]
18. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis.
Yamaguchi N; Fujii T; Aoi S; Kozuch PS; Hortobagyi GN; Blum RH
Eur J Cancer; 2015 Nov; 51(16):2314-20. PubMed ID: 26343314
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms and management of doxorubicin cardiotoxicity.
Shi Y; Moon M; Dawood S; McManus B; Liu PP
Herz; 2011 Jun; 36(4):296-305. PubMed ID: 21656050
[TBL] [Abstract][Full Text] [Related]
20. Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance.
Al-Malky HS; Al Harthi SE; Osman AM
J Oncol Pharm Pract; 2020 Mar; 26(2):434-444. PubMed ID: 31594518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
